Orum Therapeutics
A private, clinical-stage biotech pioneering the development of cell-specific, targeted protein degraders (TPD²) and stabilizers (TPS²) with the precision of antibody targeting to improve cancer treatment for more patients.
The lead therapeutic candidate from the TPD² GSPT1 platform, ORM-5029, is in clinical development for the treatment of HER2-expressing solid tumors.
The TPS² approach uses proprietary Cbl-b inhibitor payloads conjugated to immune cell- or tumor cell-targeting antibodies. Orum is located in Boston, USA, and Daejeon, South Korea.
Latest Orum Therapeutics News & Features
6 November 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze